Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278821
Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving...
Conclusion: Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations.
Share
SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
Source : https://www.thno.org/v13p0531.htm
Theranostics 2023; 13(2):531-542. doi:10.7150/thno.80289 This issue Cite Research Paper Nunzia D'Onofrio 1*, Francesco Prattichizzo 2*, Raffaele Marfella 3,4, Celestino Sardu 3, Elisa Martino 1, Lucia Scisciola 3, Lorenza Marfella 3,...
Conclusions: Overall, these data suggest that PCSK9i bear intrinsic anti-inflammatory, anti-autophagic, and antioxidant properties in endothelial cells, and that these pleiotropic effects might be mediated, at least in part, by SIRT3. These results provide an additional mechanism supporting the emerging knowledge relative to the benefit of...
Share
-
Lipid Management Connect3yrKey Points • Source: Theranostics • Conclusions: “Overall, these data suggest that PCSK9i bear intrinsic anti-inflammatory, anti-autophagic, and antioxidant properties in endothelial cells, and that these pleiotropic effects might be mediated, at least in Show More
Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial H ...
Source : https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-22-0445/_article
Background: This study evaluated the safety and effectiveness of alirocumab in Japanese patients with familial hypercholesterolemia (FH) or non-FH in a real-world clinical setting. Methods and Results: This post-marketing surveillance study had...
Conclusions: Alirocumab was well tolerated and showed effectiveness in Japanese patients with hypercholesterolemia in a real-world clinical setting.
Share
Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis
Source : https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63899/_article
Aim: Serum levels of cholesterol absorption and synthesis markers are known to be associated with cardiovascular risk. Familial hypercholesterolemia (FH) is a well-known inherited disorder presenting elevated low-density lipoprotein cholesterol...
Conclusion: FH group had significantly elevated serum Campe and Sito concentrations and insignificantly elevated Latho concentrations; thus, intestinal cholesterol absorption relative to hepatic cholesterol synthesis was suggested to be elevated in patients with FH. Serum Latho, Campe, and Sito concentrations showed nonlinear associations with...
Share
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review
Source : https://www.sciencedirect.com/science/article/pii/S2666087322004690?via=ihub
As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to...
Relevance: Immune checkpoint inhibitor (ICI) therapy is associated with an increased risk of atherosclerotic CV events likely mediated by accelerated atherosclerosis.
Share